

# Tom F Brouwer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1619188/publications.pdf>

Version: 2024-02-01

34  
papers

1,719  
citations

304368

22  
h-index

414034

32  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1739  
citing authors

#	ARTICLE	IF	CITATIONS
1	Subcutaneous or Transvenous Defibrillator Therapy. <i>New England Journal of Medicine</i> , 2020, 383, 526-536.	13.9	278
2	Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2047-2055.	1.2	151
3	Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2018, 15, 1515-1522.	0.3	123
4	Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management. <i>International Journal of Cardiology</i> , 2015, 195, 126-133.	0.8	120
5	Implantable cardioverter-defibrillators in adults with congenital heart disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2016, 37, 1439-1448.	1.0	101
6	The learning curve associated with the introduction of the subcutaneous implantable defibrillator. <i>Europace</i> , 2016, 18, 1010-1015.	0.7	95
7	A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score. <i>Heart Rhythm</i> , 2019, 16, 403-410.	0.3	94
8	Association Between Chest Compression Interruptions and Clinical Outcomes of Ventricular Fibrillation Out-of-Hospital Cardiac Arrest. <i>Circulation</i> , 2015, 132, 1030-1037.	1.6	86
9	Determinants of Subcutaneous Implantable Cardioverter-Defibrillator Efficacy. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 405-414.	1.3	69
10	Acute and 3-Month Performance of Communicating Leadless Antitachycardia Pacemaker and Subcutaneous Implantable Defibrillator. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1487-1498.	1.3	57
11	Communicating Antitachycardia Pacing-Enabled Leadless Pacemaker and Subcutaneous Implantable Defibrillator. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1865-1866.	1.2	53
12	Implantation of the Subcutaneous Implantable Cardioverter-Defibrillator. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, e004663.	2.1	52
13	Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy. <i>Heart Rhythm</i> , 2016, 13, 457-463.	0.3	46
14	J Curve in Patients Randomly Assigned to Different Systolic Blood Pressure Targets. <i>Circulation</i> , 2017, 136, 2220-2229.	1.6	42
15	Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized Comparative trial of Subcutaneous Implantable Cardioverter-Defibrillator Implantation with and without Defibrillation testing. <i>American Heart Journal</i> , 2019, 214, 167-174.	1.2	41
16	Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials. <i>Diabetes Care</i> , 2018, 41, 1142-1148.	4.3	37
17	Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies. <i>Europace</i> , 2018, 20, f240-f248.	0.7	36
18	Leadless pacemaker versus transvenous single-chamber pacemaker therapy: A propensity score-matched analysis. <i>Heart Rhythm</i> , 2018, 15, 1387-1393.	0.3	35

#	ARTICLE	IF	CITATIONS
19	Initial Estimated Glomerular Filtration Rate Decline and Long-Term Renal Function During Intensive Antihypertensive Therapy. <i>Hypertension</i> , 2020, 75, 1205-1212.	1.3	33
20	Implantation of the subcutaneous implantable cardioverter-defibrillator with truncal plane blocks. <i>Heart Rhythm</i> , 2018, 15, 1108-1111.	0.3	32
21	A morphology based deep learning model for atrial fibrillation detection using single cycle electrocardiographic samples. <i>International Journal of Cardiology</i> , 2020, 316, 130-136.	0.8	28
22	Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial. <i>Circulation</i> , 2022, 145, 321-329.	1.6	28
23	Surgical Management of Implantation-Related Complications of the Subcutaneous Implantable Cardioverter-Defibrillator. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 89-96.	1.3	21
24	Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2018, 72, 1337-1344.	1.3	18
25	Complications related to elective generator replacement of the subcutaneous implantable defibrillator. <i>Europace</i> , 2021, 23, 395-399.	0.7	12
26	Long-term follow-up of the two-incision implantation technique for the subcutaneous implantable cardioverter-defibrillator. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 1476-1480.	0.5	10
27	Subcutaneous Implantable Cardioverter Defibrillator Lead Failure due to Twiddler Syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 1369-1371.	0.5	7
28	Algorithm-Based Screening May Improve Patient Selection for the Subcutaneous Implantable Defibrillator. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 605-614.	1.3	5
29	Clinical parameters to optimize patient selection for subcutaneous and transvenous implantable defibrillator therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 990-995.	0.5	5
30	¿El desfibrilador subcutáneo debe ser la primera elección en la prevención primaria de la muerte súbita?. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 142-144.	0.6	2
31	Should the Subcutaneous Implantable Defibrillator Be the First Choice for Primary Prevention of Sudden Cardiac Death?. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2017, 70, 142-144.	0.4	1
32	Blood pressure lowering treatment and the Framingham score: Do not fear risk. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1821-1822.	1.0	1
33	Letter by Brouwer et al Regarding Article, "Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry". <i>Circulation</i> , 2018, 138, 2970-2971.	1.6	0
34	Response by Kalkman et al to Letter Regarding Article, "J Curve in Patients Randomly Assigned to Different Systolic Blood Pressure Targets: An Experimental Approach to an Observational Paradigm". <i>Circulation</i> , 2018, 137, 2549-2550.	1.6	0